Paul G. Foster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Paul G. Foster has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Y. Lopez Espinoza
University of Washington School of Medicine, Seattle, WA, USA
25 shared publications - Amber E. de Groot
Arcus Biosciences, Hayward, California. 1
25 shared publications - Amita Patnaik
START, San Antonio, TX
25 shared publications - Amy E. Anderson
Arcus Biosciences, Inc., Hayward, California
25 shared publications - Carlo E. Stagnaro
Arcus Biosciences, Inc., Hayward, California
25 shared publications - Casey G. Mitchell
Arcus Biosciences, Hayward, California
25 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , E42
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
- 4 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , E42
Open AccessAuthor Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
- Open Access
- 1 July 2026
- Published by Springer Nature in Nature
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor 2α (HIF-2α) 1 . Here we show that monotherapy with casdatifan—an orally bioavailable, potent and selective HIF-2α inhibitor 2 —produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC. Dose-expansion data from the ARC-20 study ( NCT05536141 ) are presented, including for the 100 mg once daily (QD) cohort ( n = 32) and the total cohort ( n = 127). Treatment discontinuation from casdatifan-related adverse events was infrequent (3%), and class-effect toxicities included anaemia and hypoxia. The confirmed objective response rates (ORRs) were 35% (95% confidence intervals (CI) = 19–55%; 100 mg QD) and 31% (95% CI = 23–40%; total); median progression-free survival (PFS) was not estimable (95% CI = 5.7–not estimable; 100 mg QD) and 12.2 months (9.4–20.6; total). Greater maximal reductions in serum erythropoietin were associated with improved clinical outcomes, including a higher ORR ( P = 0.001), lower rates of progressive disease ( P = 0.003) and longer PFS ( P = 0.006). Erythropoietin expression was restricted to cancer cells and was significantly higher at the mRNA level in patients with clinical benefit. Concordantly, HIF-2α protein expression and HIF-2α expression signature were associated with prolonged PFS. Overall, our findings show that casdatifan achieves meaningful, durable responses with manageable safety. These data establish a link between on-target HIF-2α pathway modulation, tumour biology and clinical efficacy.
- 1 July 2026
- Published by Springer Nature in Nature
Open AccessCasdatifan shows durable response linked to HIF-2α biology in kidney cancer
Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor 2α (HIF-2α) 1 . Here we show that monotherapy with casdatifan—an orally bioavailable, potent and selective HIF-2α inhibitor 2 —produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC. Dose-expansion data from the ARC-20 study ( NCT05536141 ) are presented, including for the 100 mg once daily (QD) cohort ( n = 32) and the total cohort ( n = 127). Treatment discontinuation from casdatifan-related adverse events was infrequent (3%), and class-effect toxicities included anaemia and hypoxia. The confirmed objective response rates (ORRs) were 35% (95% confidence intervals (CI) = 19–55%; 100 mg QD) and 31% (95% CI = 23–40%; total); median progression-free survival (PFS) was not estimable (95% CI = 5.7–not estimable; 100 mg QD) and 12.2 months (9.4–20.6; total). Greater maximal reductions in serum erythropoietin were associated with improved clinical outcomes, including a higher ORR ( P = 0.001), lower rates of progressive disease ( P = 0.003) and longer PFS ( P = 0.006). Erythropoietin expression was restricted to cancer cells and was significantly higher at the mRNA level in patients with clinical benefit. Concordantly, HIF-2α protein expression and HIF-2α expression signature were associated with prolonged PFS. Overall, our findings show that casdatifan achieves meaningful, durable responses with manageable safety. These data establish a link between on-target HIF-2α pathway modulation, tumour biology and clinical efficacy.